Business news from Ukraine


As part of a stress scenario in the event of escalation of hostilities, the pharmaceutical company Interchem (Odessa) is increasing stocks of raw materials and forming additional reserves of finished products for a number of items, Director General of Interchem Anatoliy Reder has said.
“We have revised the calculation criteria and approaches to the formation of stocks of raw materials and products. For the most vulnerable stock items, we are taking all necessary measures to increase them, including allocating additional working capital for a prompt response to force majeure situations,” he told Interfax-Ukraine.
Raeder noted that recently there have been interruptions in the supply of raw materials and consumables. To a greater extent, they concerned imported products delivered by sea. However, at the same time, the top manager notes that this is a common problem for the entire pharmaceutical industry and for the Ukrainian business in general, which largely depends on external raw materials.
“I can’t say whether they are caused to a greater extent by the current political situation, or in general by global logistical problems, but today the arrival of a container with raw materials, which we expected to receive on February 15, has been postponed to February 23. I really hope that all the raw materials will arrive, as the passage of sea vessels has been resumed,” he said.
In addition, the Interchem CEO said that the company was also concerned about possible complications with the supply of raw materials, which were carried out by air freight transportation. For example, if insurance companies for cargo flights take measures similar to those they have taken in relation to passenger air travel.
“It is important for us that all directions and types of transport logistics function, since Interchem receives raw materials for production both by land, by air, and by sea,” he said.
Commenting on the issue of possible changes in the range of products, Reder noted that the company had already formed a production program and production volumes of a particular commodity item, taking into account its possible increased demand in the event of escalation of hostilities.
“We have several items that belong to the state reserve range, and for these items we have ensured the necessary stocks. They are maintained in sufficient quantities and do not depend on the needs of the open market, we will be able to immediately ship them as soon as necessary. This required additional effort and expense, but it had to be done,” he said.
In order to prevent “any kind of failure” in the production process, the company has optimized the work schedule: production has moved to a six-day work week with three shifts on weekdays. In addition, as part of the development of the stress scenario, Interchem revised a program of foreign business trips, developed an emergency plan for evacuation of employees and conservation of production, and also carries out complex equipment of a bomb shelter in one of the largest residential areas of Odessa on its own, Reder specified.
“I really hope that with such thoughtful actions we will be able to avoid a shortage of raw materials and ensure uninterrupted supply of products. After all, the main task of the company today is to mobilize as much as possible in order to ensure the stable operation of production and uninterrupted shipment of products. People should not have a reason to panic due to a shortage of essential goods, and especially medicines,” the CEO says.
Interchem is one of the leading pharmaceutical companies in the country. The company is a supplier of medicines for the programs of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Interchem is a member of the Association of Manufacturers of Medications of Ukraine.

, ,


The pharmaceutical company Interchem (Odesa), the double liability company, within the framework of patronage support, has invested UAH 2 million in the project of a unique 3D hologram of the real face of Yaroslav the Wise, which is installed in Saint Sophia Cathedral in Kyiv, Director General of Interchem Anatoliy Reder has said.
“We have invested UAH 2 million in this project. There are plans for further cooperation and new projects,” he told Interfax-Ukraine during a presentation on Thursday, March 4.
Reder noted that recent studies in Saint Sophia Cathedral’s nature reserve made it possible to visualize the authentic features of Yaroslav the Wise. Unique Danish equipment was used for visualization.
The project allows to see the face of Yaroslav the Wise, as he could have been at the age of about 45, while the canonical image of the prince, restored from his skull, creates an appearance similar to the appearance of the Russian monarchs. In this guise, Prince Yaroslav is represented at a much older age.
As reported earlier, Interchem was one of the patrons of the project to drain the foundations and walls of Saint Sophia Cathedral and adjacent monastic buildings from excess moisture using the Swiss technology BioDry.
Saint Sophia Cathedral is one of the historical sites included in the UNESCO World Heritage List. The cathedral is the spiritual center, where the unique knowledge base of the Ukrainian people for the last millennium is concentrated. Thanks to the patrons who restored the cathedral in different historical epochs after enemy invasions and natural disasters, its ancient architecture and the world’s most complete ensemble of original mosaics and frescoes of the 11th century have been preserved. It has 260 square meters of mosaics and 3,000 square meters of frescoes.

, ,

Pharmaceutical company Interchem developing new anesthetic drug

The pharmaceutical company Interchem (Odesa), the double liability company, is developing a new anesthetic drug, preparing an international dossier for it, Director General of Interchem Anatoliy Reder has said.

“The drug will be an anesthetic. It is original, completely new, it is a new molecule. We have been deeply studying it for three or four years,” he said in an exclusive interview with Interfax-Ukraine.

Reder said that the company will develop a dossier for this drug in accordance with international standards.

“For us in this project, it is important that we first thought about how to form an international dossier of the new drug. For one reason or another, we always had a dossier, either Soviet or Ukrainian. Today we understand that an international dossier is needed, and we want to try making it for this drug,” he said.

Reder said that the company has begun collaborating with an international research organization that will conduct preclinical trials of the new drug.

According to Reder’s forecasts, the development of the new drug could take one and a half or two years.

“We hope that within one and a half or two years the pills will appear in Ukraine,” he said.

Interchem is one of the leading pharmaceutical companies in the country.



Double liability company Interchem, a pharmaceutical company based in Odesa, has received the permit of the Health Ministry of Ukraine for conducting clinical testing of antiviral medicine Amixin for effectiveness in treatment of coronavirus (COVID-19).
Director General of the company Anatoliy Reder told Interfax-Ukraine that a respective decree of the Health Ministry was signed on May 14.
He also said that the company requested the consideration of the application on clinical trials of Amixin due to the fact that the medicine had previously shown its effectiveness against a number of dangerous viral infections. During preclinical trials, it was proved that tilorone (the active substance of Amixin medicine) has antiviral activity against a number of strains of ordinary coronaviruses.
Several international research centers have already conducted and are carrying out testing of tilorone against SARS-CoV-2 coronavirus.
“As we can see, not only do we consider Amixin as a potentially effective medicine against COVID-19, but also researchers abroad,” he said.
Reder said that, in particular, such trials were conducted at the Institut Pasteur Korea (South Korea), and in two research centers in the United States as well.
“Based on the data of preclinical trials showing the highly effective antiviral effect of tilorone against SARS-CoV-2, we applied to the Health Ministry for approval of the third phase of clinical testing to expand the range of use of Amixin medicine and obtain evidence on its efficiency and safety for treating patients with COVID-19 infection,” he said.
According to Reder, clinical trials of Amixin will be conducted by research centers in three cities of Ukraine. In general, a trial may take three to four months from the moment the Health Ministry gave a permit for conducting it to the pharmaceutical company.
“The duration of the clinical trial will primarily depend on the speed of patient enrollment. At this stage, it is planned to include more than 60 volunteers in the study who, according to the severity of the disease, will be on self-isolation and undergo outpatient treatment,” he said.
Reder said that the research doctors who confirmed their readiness to conduct this trial are highly motivated, first of all, by their scientific interest and the opportunity to make their contribution to the search for a solution, which is so urgent for the whole world of medical and social problem that the new coronavirus has become.
Interchem is one of the leading pharmaceutical companies in the country.

, , ,


Double liability company Interchem, a pharmaceutical company based in Odesa, has bought equipment for polymerase chain reaction (PCR) testing for the virus laboratory of the Odesa Regional Laboratory Center of the Health Ministry of Ukraine.
Interchem Director General Anatoliy Reder told Interfax-Ukraine that this equipment was the first system in the regional laboratory, which makes it possible to perform PCR testing of the COVID-19 infection.
“Until today, in Odesa region there was not a single device on which it was possible to perform such a PCR test. Odesa region was not able to perform such tests on its own, the virus laboratory of the state-owned institution Odesa Regional Laboratory Center of the Health Ministry of Ukraine was forced to act as a logistician: to collect biomaterial from the centers where it was taken, and then send it to Kyiv. Thus, the results were only on the fifth day. This is what we must avoid, as if we are forced to wait five days for a response from the laboratory, all other methods of fighting the virus are becoming meaningless,” he said.
Reder said that the system for PCR testing has already been installed and began to work.
In addition, Interchem purchased the first batch of tests for this system.
“We hope that the PCR tests, which are procured centrally, will also come to Odesa region. As world experience shows, those countries in which it was possible to achieve a high level of coverage of population with testing and diagnostics demonstrate the lowest results in mortality and the spread of infection,” Reder said.
He also said that the purchased PCR testing system will be in demand after the end of the COVID-19 pandemic.
Interchem is one of the leading pharmaceutical companies in the country.

, ,


Pharmaceutical doubled liability company Interchem will send over UAH 2.5 million to equip Odesa infectious diseases hospital with medical equipment and medicines. Interchem Director General Anatoliy Reder told Interfax-Ukraine that the company took into account the real needs of the hospital.
“Interchem joined in the fight against coronavirus. We tried to take a balanced approach, listening carefully to the needs of the infectious diseases hospital, and did not begin to deliver artificial lungs ventilators, because, according to doctors, a sufficient amount of ventilators was available. We decided to meet urgent needs which are no less important,” he said.
In particular, the company purchases a portable ultrasound machine for the hospital, which will minimize the movement of infected patients in the clinic and greatly facilitate diagnostic procedures for doctors.
In addition, Interchem buys oxygen concentrators, pulse oximeters, and other necessary equipment for the infectious diseases hospital.
“We will listen very carefully to the needs of the clinic and, above all, and respond to the requirements of medical professionals,” he said.
Reder also said that the company transferred the antiviral drug Amixin to the Odesa infectious diseases hospital, which is used, in particular, to protect medical personnel.
“We are by no means claiming that this is a drug to treat the coronavirus diseases COVID-19 circulating now, but we know for sure: this is an antiviral drug that will prevent medical personnel from getting ill with ordinary viral infections,” he said.
According to Reder, Interchem switched to a seven-day workweek because of the increased need for medications, not just from the antiviral group.
“Manufacturers today received the list of the Ministry of Health with medicines that hospitals should be provided with in accordance with WHO recommendations. This list contains drugs manufactured by Interchem,” he said, noting that this is, in particular, about painkillers, anticonvulsants and anxiolytic drugs.
Reder also said that the entire staff of the company is being transported to and from work by company buses.
“In some ways, it is easier for us, we didn’t have a problem with the delivery of people, because we always bring staff by our buses,” he said.
Reder also said that Interchem will reformat production processes in order to increase the production of the most popular drugs today and reduce the production of less relevant ones.
Pharmaceutical doubled liability company Interchem is one of the leading pharmaceutical companies in the country.

, , ,